ABL1 and ABL2 display mutations in approximately 1.5% and 4% of NSCLC cases, respectively, and ABL2 is amplified in approximately 8% of NSCLC cases (Appendix Fig S1A and B, adapted from cBio Cancer Genomics Portal). This evidence concerns the gene ABL2 and non-small cell lung carcinoma.